Perceived utility and disutility of genomic sequencing for pediatric patients: Perspectives from parents with diverse sociodemographic characteristics
Authors:
- Meghan C. HalleyMHMeghan C. Halley
- Undiagnosed Diseases NetworkUNUndiagnosed Diseases Network
Open Access
- 3 January 2022
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (4) , 1088-1101
Abstract
Given the limited therapeutic options for most rare diseases diagnosed through genomic sequencing (GS) and the proportion of patients who remain undiagnosed even after GS, it is important to characterize a broader range of benefits and potential harms of GS from the perspectives of families with diverse sociodemographic characteristics. We recruited parents of children enrolled in the Undiagnosed Diseases Network. Parents completed an in‐depth interview, and we conducted a comparative content analysis of the data. Parents (n = 30) were demographically diverse, with 43.3% identifying as Hispanic, 33.3% primarily Spanish‐speaking, and widely variable household income and education. Parents reported minimal changes in their child's health status following GS but did report a range of other forms of perceived utility, including improvements in their child's healthcare management and access, in their own psychological well‐being, and in disease‐specific social connections and research opportunities. Parents who received a diagnosis more frequently perceived utility across all domains; however, disutility also was reported by both those with and without a diagnosis. Impacts depended on multiple mediating factors, including parents' underlying expectations and beliefs, family sociodemographic characteristics, individual disease characteristics, and prior healthcare access. Our study suggests that the perceived utility of GS varies widely among parents and may depend on multiple individual, sociodemographic, and contextual factors that are relevant for pre‐ and post‐GS counseling, for value assessment of GS, and for policymaking related to access to new genomic technologies.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UL1TR003142)
- National Human Genome Research Institute (K01HG011341, T32HG008953)
- National Institutes of Health (U01HG010218, U01HG010218‐03S2)
- Stanford Maternal and Child Health Research Institute (1233211‐102‐JHAJL)
This publication has 39 references indexed in Scilit:
- The NIH Undiagnosed Diseases Program and Network: Applications to modern medicineMolecular Genetics and Metabolism, 2016
- Not the End of the Odyssey: Parental Perceptions of Whole Exome Sequencing (WES) in Pediatric Undiagnosed DisordersJournal of Genetic Counseling, 2016
- Patients’ Perceived Utility of Whole-Genome Sequencing for Their Healthcare: Findings from the Medseq ProjectPersonalized Medicine, 2016
- Implicit Racial/Ethnic Bias Among Health Care Professionals and Its Influence on Health Care Outcomes: A Systematic ReviewAmerican Journal of Public Health, 2015
- Utility of whole‐exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in careClinical Genetics, 2015
- FORGE Canada Consortium: Outcomes of a 2-Year National Rare-Disease Gene-Discovery ProjectThe American Journal of Human Genetics, 2014
- Personal utility in genomic testing: is there such a thing?Journal of Medical Ethics, 2014
- The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disordersGenetics in Medicine, 2014
- Personal utility and genomic information: Look before you leapGenetics in Medicine, 2009
- Using Pooled Kappa to Summarize Interrater Agreement across Many ItemsField Methods, 2008